LifeStance Health Group, Inc.

LFST Healthcare Medical Care Facilities

LifeStance Health Group, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 13.9% from fiscal 2024. In the quarter to June 2026, revenue grew 26.1%, EPS grew 700.0%, free cash flow grew 55.2% and total debt fell 5.08%, each against the same quarter a year earlier. Revenue growth for five consecutive years.

11.74 0.63 −5.09%
Market cap
$4.7B
P/E
88.3×
Fwd P/E
58.5×
Dividend yield
—
F-score
8/9
Altman Z
2.65
Beneish M
−2.96
Dividend safety
n/a

LifeStance Health Group, Inc. (LFST) EV/Sales

Alert me on EV/Sales

As of 16 October 2026, LifeStance Health Group, Inc. (LFST) trades at a EV/Sales of 2.9×. Over the past ten years it has ranged from 1.2× (August 2025) to 20.5× (June 2021); the current reading is higher than 61% of that period. That is above the Medical Care Facilities industry median of 1.3× and below the Healthcare sector median of 3.4×.

EV/Sales, daily

Embed this chart

Annual newest first

Period EV/Sales Change
FY2025 1.9× (17.73%)
FY2024 2.3× (20.64%)
FY2023 2.9× 42.93%
FY2022 2.1× (56.09%)
FY2021 4.7× (70.23%)
FY2020 15.7× 0.00%
FY2019 15.7× —

Quarterly newest first

Period EV/Sales Change
Jun 2026 2.6× 54.08%
Mar 2026 1.7× (11.69%)
Dec 2025 1.9× 19.70%
Sep 2025 1.6× 1.36%
22 more quarters

Against its own ten years

Low 1.2× High 20.5×
Ten-year median 2.5×
Current reading's percentile 61

EV/Sales against peers

What EV/Sales is

EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)

The full definition of EV/Sales →

More on LFST